[1]Cronin KA, Harlan LC, Dodd KW, Abrams JS, Ballard-Barbash R. Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US. Cancer Invest (2010) 28(9):9...
et al. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 22, 85–97 (2021). Article CAS Google Scholar Konecny, ...
[14]Pérez-García JM,Gebhart G,Ruiz Borrego M,et al.Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer(PHERGain):a multicentre,randomised,open-label,...
Breast cancer represents the most commonly diagnosed neoplasm worldwide and the HER2-positive subtype accounts for nearly 1 in 5 breast cancers. The majority of patients with breast cancer present with an early-stage disease upon diagnosis, which is thus susceptible to virtually curative treatment str...
Harbeck N, Wrobel D, Zaiss M, et al. Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study. Breast Care. 2023. ...
Alvaro Moreno-Aspitia11, Martine Piccart10, Marianne Paesmans3, Evandro de Azambuja 1 and Matteo Lambertini 16,17 ✉ 8, The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted ...
13. Harbeck N, Wrobel D, Zaiss M, et al. Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study. Breast Care. 2023. ...
[1]. Junjie Li, Zhonghua Wang, Zhimin Shao, et al. HER2-Directed Antibody-Drug Conjugate SHR-A1811 in the Neoadjuvant Treatment of HER2-positive Early Breast Cancer: a Prospective, Randomized, Open-label, Phase 2 Trial. 2024 SABCS GS1-04....
7、Sibylle Loibl,et al.“Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy:KATHERINE final IDFS and updated OS analysis.”2023 SABCS Abstract GS03-12. ...
[4]Qian He,et al.Efficacy of neoadjuvant single or dual anti-HER-2 therapy combined with chemotherapy in patients with HER-2-positive breast cancer:a single-center retrospective study.Asian Pac J Cancer Prev.2021 May 1;22...